NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE
Post# of 341
(Total Views: 183)
Posted On: 09/03/2021 3:50:57 PM
NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Featured in Article as Stock That Is ‘Shaping up to Be a Brilliant Investment’
Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company focused on advancing psychedelic pharmaceutical therapeutics for various psychiatric and neurological conditions, was highlighted in a Motley Fool article titled, “Buying Cybin Stock Right Now Could Be a Brilliant Move.” The piece, written by Alex Carchidi, delves into CYBN as one of those investment opportunities in places outside the mainstream. “Cybin (NYSE: CYBN) is a biotech that’s developing mental illness treatments derived from widely illegal psychedelic chemicals like psilocybin (best known as the active compound in ‘magic mushrooms’). Based on a swath of extremely positive coverage in the scientific literature, I’m of the opinion that these psychedelic therapies are going to be a tremendous force for good — and investor returns — over the coming years. And Cybin could well be one of the leaders in the psychedelics space, so let’s take a look at why it’s shaping up to be a brilliant investment,” reads the article. “Cybin has a few technologies that will give it an edge in the market for psychedelics, assuming it eventually gets a drug approved for sale.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company focused on advancing psychedelic pharmaceutical therapeutics for various psychiatric and neurological conditions, was highlighted in a Motley Fool article titled, “Buying Cybin Stock Right Now Could Be a Brilliant Move.” The piece, written by Alex Carchidi, delves into CYBN as one of those investment opportunities in places outside the mainstream. “Cybin (NYSE: CYBN) is a biotech that’s developing mental illness treatments derived from widely illegal psychedelic chemicals like psilocybin (best known as the active compound in ‘magic mushrooms’). Based on a swath of extremely positive coverage in the scientific literature, I’m of the opinion that these psychedelic therapies are going to be a tremendous force for good — and investor returns — over the coming years. And Cybin could well be one of the leaders in the psychedelics space, so let’s take a look at why it’s shaping up to be a brilliant investment,” reads the article. “Cybin has a few technologies that will give it an edge in the market for psychedelics, assuming it eventually gets a drug approved for sale.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)